(Reuters) -U.S. Health Secretary Robert F. Kennedy Jr.'s surprise ouster of a national vaccine advisory board, claiming it ...

Pfizer's stock ended the day up slightly, rising 0.35% to $24.39, after a volatile session that started strong, dipped, then ...

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

Pfizer’s CEO Albert Bourla disclosed that the company recently met with the Trump administration to discuss lowering U.S.

With Main Street investors now able to trade as fast as some qualitative hedge funds, seismic changes could be ahead for the ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Pfizer is gearing up for a federal preemption defense, its first fight designed to wipe out more than 400 lawsuits over ...

Axsome Therapeutics has hit a costly snag in its mission to bring esreboxetine to market for fibromyalgia. | Axsome ...

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Under terms of the deal, Bristol Myers will pay $1.5 billion upfront, and a total of $2 billion in anniversary payments for the next few years to co-develop and co-sell BioNTech's BNT327 for the ...

Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 ...